GH Research (NASDAQ: GHRS) to participate in 38th ECNP 2025 meeting

Rhea-AI Filing Summary

GH Research PLC filed a report stating that it will participate in the 38th European College of Neuropsychopharmacology annual meeting, scheduled for October 11-14, 2025 in Amsterdam, the Netherlands. The company highlights this scientific and medical conference appearance through an attached press release, which is included as an exhibit.

The report notes that the press release is provided as of October 9, 2025 and clarifies that its availability should not be seen as an admission that the information is material. GH Research also states it does not undertake any obligation to update that press release or its forward-looking statements after that date.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025.

Commission File Number: 001-40530

GH Research PLC

(Exact name of registrant as specified in its charter)

Joshua Dawson House
Dawson Street

Dublin 2

D02 RY95

Ireland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F  ☐

GH Research PLC (the “Company”) announces its participation at the 38^th European College of Neuropsychopharmacology (ECNP) annual meeting, which is scheduled to take place from October 11-14, 2025, in Amsterdam, the Netherlands.

A copy of the press release is attached hereto as Exhibit 99.1.

The fact that this press release is being made available should not be deemed an admission as to the materiality of any information contained therein. The information contained in the press release is being provided as of October 9, 2025, and the Company does not undertake any obligation to update the press release in the future or to update forward-looking statements to reflect subsequent actual results.

1

EXHIBIT INDEX

99.1 Press release dated October 9, 2025

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GH Research PLC
Date: October 9, 2025
	By:	/s/ Julie Ryan
	Name:	Julie Ryan
	Title:	Vice President, Finance

3

FAQ

What did GHRS disclose in its latest 6-K filing?

The filing states that GH Research PLC will participate in the 38th European College of Neuropsychopharmacology (ECNP) annual meeting in Amsterdam, scheduled for October 11-14, 2025, and that related details are provided in an attached press release.

When and where is GHRS participating in the ECNP 2025 meeting?

GH Research PLC plans to participate in the 38th ECNP annual meeting, which is scheduled to take place from October 11-14, 2025 in Amsterdam, the Netherlands.

What is included as an exhibit in the GHRS 6-K?

The report includes as Exhibit 99.1 a press release related to GH Research PLC's participation at the 38th ECNP annual meeting.

Does GH Research PLC consider the ECNP press release to be material information?

The company states that making the press release available should not be deemed an admission as to the materiality of any information contained in it.

As of what date is the GHRS press release information provided?

The information in the press release is stated to be provided as of October 9, 2025.

Is GH Research PLC obligated to update the ECNP-related press release?

GH Research PLC states that it does not undertake any obligation to update the press release in the future or to update any forward-looking statements to reflect subsequent actual results.

Who signed the GHRS 6-K report?

The report was signed on behalf of GH Research PLC by Julie Ryan, who is identified as Vice President, Finance.